Exogenously increasing miR-146a levels ameliorates GVHD. (A-C) WT C57BL/6 T cells were transfected with a miR-146a mimic or an NC mimic before transplantation into allogeneic (BALB/c) recipient mice (5 × 105 T cells per mouse). (A) Transfection efficiency was confirmed by qRT-PCR for miR-146a. (B) Survival and (C) GVHD histopathology scores of recipients are depicted. Data were pooled from 2 independent experiments. (D-F) Allo-HCT was performed as described on BALB/c mice using C57BL/6 donors. (D) Mice were treated with the miR-146a mimic or NC mimic in in vivo-jetPEI intraperitoneally on days 2, 5, and 7. miR-146a expression in the spleens and livers of recipient mice was analyzed by qRT-PCR on day 7 after allo-HCT. (E) Survival curves and (F) GVHD histopathology scores are shown. (G-H) WT BALB/c T cells were transfected with a miR-146a mimic or a NC mimic before transplantation into allogeneic (C57BL/6) recipient mice (5 × 105 T cells per mouse). (G) Transfection efficiency was confirmed by qRT-PCR for miR-146a. (H) The small intestine, colon, and liver were isolated on day 7 after allo-HCT and scored for GVHD histopathology.
